Nordic Nanovector ASA (OSE: NANO), a company focusing on the development
and commercialisation of novel targeted therapeutics in haematology and
oncology, will announce its second quarter 2015 results on Wednesday, 26
August 2015.
A presentation by Nordic Nanovector’s senior management team will take
place at 8:30 am CEST at:
Thon Hotel Vika Atrium
Munkedamsveien 45
0250 Oslo
Meeting Room: NYLAND
The presentation will be recorded as a webcast and will be available
after the event on www.nordicnanovector.com
in the section: Investor Relations/Webcast.
The results report and the presentation will be available at www.nordicnanovector.com
in the section: Investor Relations/Reports and Presentation/Quarterly
Reports from 7:00 am CEST the same day.
###
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company’s lead clinical-stage product opportunity is
Betalutin™, the first in a new class of Antibody-Radionuclide-Conjugates
(ARC) designed to improve upon and complement current options for the
treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with
substantial unmet medical need and orphan drug opportunities,
representing a growing market worth over USD 12 billion by 2018.
Betalutin™ comprises a tumour-seeking anti-CD37 antibody (HH1)
conjugated to a low intensity radionuclide (lutetium- 177). It has shown
promising efficacy and a favourable safety profile in a Phase 1/2 study
in a difficult-to-treat NHL patient population. The Company is aiming at
rapidly developing Betalutin™ for the treatment of major types of NHL
with first approval anticipated by the end of 2018.
Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin™ in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline to
treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
Forward-looking statement
This announcement may contain certain forward-looking statements and
forecasts based on uncertainty, since they relate to events and depend
on circumstances that will occur in the future and which, by their
nature, will have an impact on Nordic Nanovector’s business, financial
condition and results of operations. The terms “anticipates”, “assumes”,
“believes”, “can”, “could”, “estimates”, “expects”, “forecasts”,
“intends”, “may”, “might”, “plans”, “should”, “projects”, “will”,
“would” or, in each case, their negative, or other variations or
comparable terminology are used to identify forward-looking statement.
There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in a
forward-looking statement or affect the extent to which a particular
projection is realised. Factors that could cause these differences
include, but are not limited to, implementation of Nordic Nanovector’s
strategy and its ability to further grow, risks associated with the
development and/or approval of Nordic Nanovector’s products candidates,
ongoing clinical trials and expected trial results, the ability to
commercialise BetalutinTM, technology changes and new products in Nordic
Nanovector’s potential market and industry, the ability to develop new
products and enhance existing products, the impact of competition,
changes in general economy and industry conditions and legislative,
regulatory and political factors.
No assurance can be given that such expectations will prove to have been
correct. Nordic Nanovector disclaims any obligation to update or revise
any forward-looking statements, whether as a result of new information,
future events or otherwise.
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20150818005601/en/
Copyright Business Wire 2015